| INTRODUC TI ON
Despite advances in our understanding of the pathophysiology of type 2 diabetes (T2D) and its treatment, approximately half of patients fail to achieve accepted blood glucose targets, placing them at increased risk of diabetes-related complications and increased long-term healthcare costs. 1, 2 Treatment with a single glucose-lowering agent will only address limited pathophysiological defects, necessitating the use of multiple medications in most patients to achieve adequate glycaemic control. 2 The resulting polypharmacotherapy typical of many daily anti-hyperglycaemic drug regimens carries a high burden of treatment resulting from treatment-related effects and self-care demands that are seldom adequately explored during clinical encounters. 3 Polypharmacotherapy may result in poor treatment adherence, suboptimal glucose control and increased costs, particularly when patients perceive a high medication burden. 4, 5 In older patients in particular, polypharmacotherapy associated with intensive treatment increases the risk of hypoglycaemia, which can be severe, especially when insulin secretagogues are used. 6 Polypharmacotherapy in older people is also associated with an increased risk of adverse drug reactions, medication nonadherence, falls, confusion and medication errors. 7, 8 The real-world findings of a large managed-care claims database in the USA reported that ~33% of adult patients with T2D were receiving three or more oral antidiabetes drugs (OADs) at the time of basal insulin initiation; another ~40% of patients were on two OADs. 9 Consistent with the difficulties shown in this study in not only achieving glycaemic control, but also with maintenance of euglycaemia in T2D, a similar study reported that the addition of a third OAD to background therapy of 2 OADs did not translate into improved glycaemic control compared with patients adding insulin as a third agent, despite the higher treatment persistence. 10 Regimen complexity in addition to hypoglycaemia risk may therefore be a barrier to the successful management of T2D.
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The aim of this study was to determine whether the use of insulin glargine 300 U/mL (Gla-300) compared with insulin glargine 100 U/mL (Gla-100) in insulin-naive patients enables a reduction in prior OAD burden without compromising glycaemic control and while preserving the lower incidence of hypoglycaemia events associated with Gla-300, compared with Gla-100. 12 To this end, we conducted an analysis of patient-level data from the randomized controlled EDITION 3 trial that evaluated Gla-300 compared with Gla-100 in an insulin-naive T2D population, 13 and further assessed, in a real-world setting, the impact of initiating basal insulin with Gla-300 and Gla-100 on OAD use.
| ME THODS

| Study design and patients
This was a post hoc analysis of patient-level data from the randomized controlled EDITION 3 clinical trial (NCT01676220), and deidentified data from the Clinformatics real-world claims database.
EDITION 3 was a multicentre, randomized, open-label, two-arm, parallel-group phase 3a study conducted from August 2012 to September 2013, involving 878 participants with T2D. 13 The study comprised a 2-week screening phase and a 6-month treatment period followed by a 6-month safety-extension period. 
| End-points
Study end-points for patients from EDITION 3 treated with Gla-300 compared with Gla-100 were reduction in prior OAD burden, glycaemic control, and hypoglycaemia (≤70 mg/dL and ≤54 mg/dL) incidence.
The Clinformatics database was used to address the research questions of whether there is a reduction in OAD use after initiation of Gla-300 or Gla-100 in the real world, and which OADs are impacted.
| Statistical analyses
Efficacy and safety end-points were summarized using descriptive sta- 
| RE SULTS
| Baseline characteristics and disposition
From the EDITION 3 data set, a total of 435 patients treated with Gla-300 and 437 patients treated with Gla-100 were included in the present analysis. At baseline, most patients treated with Gla-300 or Gla-100
were receiving 2 OADs as background therapy (Gla-300: n = 226 [52%];
Gla-100: n = 206 [47%]). In the Gla-300 group, 129 (30%) and 73 (17%)
patients were receiving 1 and 3 OADs, respectively, as background therapy; in the Gla-100 group, 134 (31%) and 84 (19%) patients were receiving 1 and 3 OADs, respectively, as background therapy. For patients assigned to Gla-300 vs Gla-100 in EDITION 3, baseline HbA1c and fasting plasma glucose (FPG) values are summarized by number of OADs at baseline and at Month 6 ( Table 1) . Mean HbA1c values at baseline were similar for patients treated with Gla-300 or Gla-100. insulin with Gla-300 and 83 885 initiated Gla-100. Of these, 267 and 6163 patients, respectively, met eligibility criteria and were included in the analyses.
| Change in OAD use
In the EDITION 3 data set, adding basal insulin allowed for a reduction in background OAD medication use at Month 6 among patients treated with Gla-300 (P < 0.0001), with an increase in patients receiving 0 or 1 OADs and a decrease in patients receiving 2 or 3 OADs (Figure 2A ).
Adding Gla-100 also allowed for a reduction in background OAD use at Month 6 ( Figure 2B ). In both Gla-300-and Gla-100-treated patients, there were notable decreases in the numbers of patients using 2 or 3
OADs from baseline to Month 6 (3 OADs [Gla-300: n = 73 to n = 6; Gla-100: n = 84 to n = 9]; and 2 OADs [Gla-300: n = 226 to n = 95; Gla-100: n = 206 to n = 90]). Compared with baseline, where most patients (70%) were on a background therapy of 2 or more OADs, at Month 6 a total of 314 (72%) and 22 (5%) Gla-300-treated patients were using 1 and 0 OADs, respectively. Similarly, in the Gla-100 arm, 312 (72%) and 26 (6%) patients were receiving 1 or 0 OADs at Month 6, respectively. Most of the reduction in OAD burden occurred in the first month after starting Gla-300 and was maintained throughout the duration of the study (data not shown).
Similar to the observations in the clinical trial setting, in the Clinformatics data set adding Gla-300 or Gla-100 allowed for a reduction in background OAD medication. Again, notable decreases from baseline were observed in the number of patients at Month 6 using 3
OADs (Gla-300: n = 50 to n = 31; Gla-100: n = 914 to n = 619), 2 OADs (Gla-300: n = 119 to n = 97; Gla-100: n = 2364 to n = 1911) and, in the case of Gla-100, 1 OAD (Gla-100: n = 2607 to n = 2486). Compared with baseline where most patients (70%) treated with Gla-300 were on BMI, body mass index; FPG, fasting plasma glucose; Gla-100, insulin glargine 100 U/mL; Gla-300, insulin glargine 300 U/mL; HbA1c, glycated haemoglobin; OAD, oral antidiabetes drug; SD, standard deviation. and 32 (12%) Gla-300 patients were using 1 or 0 OADs, respectively. At Month 6, 32 of 267 (12%) Gla-300-treated patients and 853 of 6163 (14%) Gla-100-treated patients were no longer taking any OADs.
| Reduction in OAD use by class of OAD
Percentage of reduction in background OAD medications is summarized by class of OAD among patients treated with Gla-300/Gla-100 F I G U R E 1 Disposition of patients from the Clinformatics database. Abbreviations: Gla-100; insulin glargine 100 U/mL; Gla-300, insulin glargine 300 U/mL; GLP-1 RA, glucagon-like peptide-1 receptor agonist; OAD, oral antidiabetes drug; Q, quarter; T2D, type 2 diabetes.
F I G U R E 2
Comparison of OAD use at baseline and 6 mo in patients treated with (A) Gla-300 and (B) Gla-100 in EDITION 3
in EDITION 3 ( Figure 3A ) and Gla-300/Gla-100 in the Clinformatics database ( Figure 3B ).
In EDITION 3, consistent with the protocol-mandated cessation of
OADs that are incompatible for use with insulin, the largest reduction in OAD use was for sulfonylureas (96% reduction). However, the use of combination OADs was reduced by 49%, thiazolidinediones by 28%
and dipeptidyl peptidase-4 (DPP-4) inhibitors by 22% ( Figure 3A ).
Among patients in the Clinformatics real-world database where there was no specifically mandated reduction of OADs, sulfonylurea use was reduced by 22%, with notable reductions also observed for thiazolidinediones (27%), DPP-4 inhibitors (22%) and meglitinide (20%) ( Figure 3B ). The only drug class to show an increase following initiation of basal insulin was the GLP-1 RA class for which a 12% increase in use was observed for Gla-300 (data not shown), compared with an overall slight decrease for the combined Gla-300/Gla-100 Clinformatics cohort.
| Glycaemic benefit and hypoglycaemia in EDITION 3
In EDITION 3, the reduced number of OADs taken by patients treated with Gla-300 or Gla-100 did not compromise glycaemic benefit or the reduced risk of hypoglycaemia that Gla-300 offers in comparison to Moreover, the lower incidence of hypoglycaemia previously observed with Gla-300 when compared with Gla-100 was also maintained following the reduction of OAD burden, as shown. In patients who were able to reduce OAD utilization from baseline, the percentage of patients with any documented symptomatic hypoglycaemia (blood glucose ≤70 mg/dL) was 30.5% with Gla-300 compared with 41.0% with Gla-100 (P = 0.0442; Figure 4A ); the percentage with any nocturnal documented symptomatic hypoglycaemia (≤70 mg/dL) was 11.9% with Gla-300 compared with 16.8% with Gla-100 (P = 0.1969; Figure 4C ). Documented symptomatic hypoglycaemia and nocturnal documented symptomatic hypoglycaemia (≤54 mg/dL) also occurred significantly less frequently for patients treated with Gla-300 compared with Gla-100: the percentage of patients with documented symptomatic hypoglycaemia (≤54 mg/dL) was 8.5% with Gla-300 compared with 18.6% with Gla-100 (P = 0.0060; Figure 4B) ; the percentage of patients with nocturnal documented symptomatic hypoglycaemia (≤54 mg/dL) was 2.3% with Gla-300 compared with 7.5% with Gla-100 (P = 0.0247; Figure 4D ).
| D ISCUSS I ON
The or Gla-100. Collectively, these observations suggest that when adding basal insulin, some patients with T2D can safely reduce their prior OAD burden while achieving an improvement in glycaemic control and at the same time preserving the known lower incidence of hypoglycaemia associated with Gla-300 compared with Gla-100.
The finding that patients with T2D who initiate or intensify therapy with insulin may benefit from reduced OAD usage is not unique.
Analysis of data from a large US managed-care database showed that in patients already receiving basal insulin, the addition of insulin aspart led to a reduction in OAD usage. 14 However, there is a surprising shortage of relevant data regarding this phenomenon, perhaps because it may be considered counterintuitive to reduce the overall therapeutic burden in a disease that is complex and progressive. On the one hand, for those patients initiating insulin therapy, it would make sense to discontinue insulin secretagogues (such as sulfonylureas). 15 On the other hand, however, discontinuing other classes of OAD with different mechanisms of action may reduce the possibilities to further decrease HbA1c levels and modify noninsulin-dependent physiological targets. For example, discontinuing an OAD with a pronounced postprandial glucose-lowering effect would potentially be counterproductive due to a loss in potential synergy with the FPG-lowering effects of insulin glargine. 16 Speculation concerning the suboptimal treatment effects of an insulin-based regimen in the context of reduced OAD burden needs
Percentage of patients on Gla-300 and Gla-100 with at least 1 hypoglycaemia event during the 6-mo treatment period in EDITION 3 who reduced prior OAD use: A, all documented symptomatic hypoglycaemia (≤70 mg/dL); B, all documented symptomatic hypoglycaemia (≤54 mg/dL); C, nocturnal documented symptomatic hypoglycaemia (≤70 mg/dL); D, nocturnal documented symptomatic hypoglycaemia (≤54 mg/dL) to be weighed against the potential benefits of regimen simplification in T2D, which include improved glycaemic control, medication adherence and reduced healthcare costs. 17, 18 In our study, we found a small increase in the use of GLP-1
RAs among patients who initiated treatment with Gla-300 in the Clinformatics database. This finding is somewhat surprising when compared to what we observed with regard to OADs. This might be due to the fact that these patients were more likely to be under the care of an endocrinologist, 19 Clinformatics datasets, the data regarding OAD usage were consistent and lend credibility to the findings overall. As a retrospective analysis, the findings were exploratory in nature and, as such, cannot be used to establish causality of the observed outcomes. Finally, a limitation of the statistical analyses employed for this study include that two sample t tests assume normally distributed data in the EDITION 3 and Clinformatics populations, and the chi-square test is sensitive to small sample size and expected frequencies.
In conclusion, our findings suggest that T2D patients who initiate basal insulin therapy with Gla-300 could potentially reduce their use of OADs without compromising glycaemic control and with a lower risk of hypoglycaemia than with Gla-100. These findings have important ramifications for real-world clinical decision-making, particularly regarding regimen simplification, but require confirmation in prospective studies. 
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